Correlation between blood urea nitrogen level and cochlear outer hair cell function in non-dialysis chronic kidney disease patients

Nyilo Purnami,1 Alfarika Roosmilasari,1 Artono Artono,1 Nunuk Mardiana2

1Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine, Soetomo Academic Medical Center, Surabaya, Indonesia; 2Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga - Soetomo Academic Medical Center, Surabaya, Indonesia

Abstract

Background: Hearing loss due to impaired cochlear function, which results from increased blood urea nitrogen (BUN) level, is one of the important clinical problems in chronic kidney disease (CKD) patients with uremia. This study aims to determine correlation between blood urea nitrogen (BUN) levels and cochlear outer hair cell (OHC) dysfunction in non-dialysis stage 3-5 CKD patients so that the BUN levels may also be used to determine the presence of cochlear OHC dysfunction.

Design and methods: An observational analytic study with a cross sectional design and consecutive sampling. This study was conducted from November 2019 to February 2020 at the Department of Internal Medicine, Soetomo Hospital, Surabaya, Indonesia, and Otorhinolaryngology-Head and Neck Surgery Department, Soetomo Hospital, Surabaya, Indonesia. Non-dialysis CKD patients who met the inclusion and exclusion criteria were subjected to a Distortion Product Otoacoustic Emissions (DPOAE) test to assess cochlear OHC function at the Otorhinolaryngology-Head and Neck Surgery, Soetomo Hospital, Surabaya.

Results: Female patients were in larger number than male patients in a ratio of 1 : 2. Most of the patients were between 51-60 years of age. DPOAE distribution was refer in 25 patients (83.3%) and pass in 5 patients (16.7%). The highest pass was at 2000 Hz in 24 patients (80.0%), while the refer results were mostly at 12,000 Hz in 29 patients (96.7%). The highest average signal to noise ratio (SNR) was at 2000 Hz and 4000 Hz (12.77 dB and 11.13 dB), while the lowest at 11,000 Hz and 12,000 Hz (1.60 dB and 1.03 dB). Pearson’s correlation test on DPOAE results did not show a significant correlation (p>0.05) between BUN levels and impaired cochlear OHC function.

Conclusions: There was no correlation between increased blood urea nitrogen levels and cochlear outer hair cell function disorders in non-dialysis patients with CKD stage 3-5.

Introduction

Hearing loss is the most commonly found disability in the world, with a prevalence of 5% of the world’s population, which equals to 466 million people.1 Chronic kidney disease (CKD) contributes to the high prevalence of hearing loss, reaching 45% to 80%.2,4 Chronic kidney disease may cause malfunctioning of several organs, including the auditory organs and the vestibular system.2

The high prevalence of hearing loss in CKD patients is an aspect that needs to be considered in the management of CKD patients, so it is necessary to carry out monitoring with hearing tests.3 Chronic kidney disease is strongly suspected as a cause of sensorineural hearing loss. However, a study on this subject revealed controversial results.6 Several studies of CKD patients had successfully demonstrated the presence of hearing impairment, mainly due to impaired cochlear function, but many other studies had found no evidence.2,6

A study by Seo et al. found a significant correlation between hearing loss and risk factors for blood urea nitrogen (BUN), glomerular filtration rate, serum and urine albumin, urine creatinine, systolic and diastolic blood pressure with p<0.05.7 A study Krishnan et al., in 89 patients with CKD found a significant correlation between sensorineural hearing loss with CKD stage and age, but not significant with BUN values, serum creatinine, hemoglobin, sodium, potassium and serum calcium.8

In chronic kidney disease the body fails to excrete the waste protein metabolism, resulting in high concentrations of urea, creatinine and uric acid.9 Urea increases serum osmolarity, resulting in a different osmotic gradient between endolymph and perilymph fluid. The osmotic effect of urea causes a decrease in the amount of endolymph fluid, which can affect hearing.10 In uremic conditions, there is inhibition of the action of the cochlear sodium potassium adenosine triphosphatase (Na+/K+ATPase) pump, which results in a decrease in endocochlear potential.11 Inhibition of Na+/K+ATPase will reduce endocochlear potential and cause disruption of water osmosis regulation to cells so that the cells become edema until lysis.12 Osmotic change causes outer hair cell (OHC) damage, endolymphatic space collapse, edema and cochlear support cell atrophy.13

The otoacoustic emission examination (OAE) has a sensitivity of 95% and a specificity of 90% so it is sensitive for the detection of cochlear dysfunction. OAE examination is widely used to evaluate OHC function because it is objective, accurate, having specific frequency, automatic, easy procedure, non-invasive, fast and...
practical. Hearing loss in CKD patients is generally subclinical, with normal ANM results, but the distortion product otoacoustic emissions (DPOAE) results are abnormal.

Therefore, it is necessary to conduct a study to prove the correlation between the function of the outer hair cell cochlea based on DPOAE examination and blood urea nitrogen levels in CKD patients at Soetomo Hospital, Surabaya, Indonesia.

### Design and methods

This study has been conducted under the authorization of the Ethic Committee of Soetomo Hospital, Surabaya, with ethical clearance number 1661/KEPK/IX/2019.

This study was an analytic observational study with a cross-sectional design. The research sample was CKD stage 3-5 patients aged 18-60 years who came for treatment at the Internal Medicine Clinic, Soetomo, Surabaya, Indonesia, from November 2019 to February 2020, with a normal tympanogram. Patients who underwent regular hemodialysis, worked in noisy places or had been exposed to explosions, had experienced head trauma, had a family history of hearing loss, had a hereditary disease (Alport’s syndrome), used long-term ototoxic drugs (e.g., aminoglycosides, cytostatics and quinolones), had a history of fever that caused hearing problems (Mumps, Rubella, and Meningitis), had a neurologic disease that could cause hearing loss (multiple sclerosis), and heavy smoking were excluded.

The samples involved comprised 30 patients and subjected to DPOAE examination using GSI Corti brand made in Denmark at a frequency of 1500 Hz to 12000 Hz. The examination result criteria were pass and refer for each frequency based on the signal to noise ratio (SNR) value. The SNR value on DPOAE obtained from the difference in DP amplitude was compared with the noise floor (NF) at each frequency. SNR value ≥6 was regarded as pass and <6 as refer. Age, sex, and laboratory data were taken from medical record data with a maximum time span of 1 month from the DPOAE examination. Data analysis used Pearson’s correlation test with 95% confidence intervals.

### Results

Results showed that there were more female patients than males. Ratio between male and female patients was 1:2 (Table 1). The age distribution of the samples showed that most of the patients belonged to 51-60 years age group, consisting of 17 patients (56.7%), followed by 41-50 years age group of 9 patients (30.0%). The youngest age was 30 years old, while the oldest was 60 years. The mean age of the study sample was 49.23 (+8.09 years) (Table 1). DPOAE distribution showed refer in 25 patients (83.3%). The most refer results were at the frequency of 12,000 Hz and the smallest at the frequency of 12,000 Hz in only 1 patient (3.3%). The most refer results were at the frequency of 12,000 Hz in as many as 29 patients (96.7%). The results of DPOAE examination based on the value of the signal to noise ratio (SNR) for each frequency showed the highest average SNR was at the frequencies of 2000 Hz and 4000 Hz, i.e. 12.77 dB and 11.13 dB, while the lowest average SNR was at frequencies of 11,000 Hz and 12,000 Hz, i.e. 1.60 dB and 1.03 dB. Pearson’s correlation test did not show a significant correlation between BUN levels and impaired cochlear OHC function based on the DPOAE results; p-values >0.05 were obtained at all frequencies (Table 3).

### Discussion

Chronic kidney disease is a multi-organ dysfunction characterized by a slow but progressive decline in kidney function. The correlation between kidney function and hearing loss has been extensively studied, but the results are controversial. Various factors are thought to cause hearing loss in CKD, including the presence of the same antigen to the kidney and cochlea that causes autoimmunity, impaired transport of electrolytes through membranes, or the presence of uremic toxins. Chronic kidney disease can cause malfunctioning of several organs, including the auditory organs and the vestibular system. Chronic kidney disease causes sensorineural hearing loss due to damage to the level of sensory organs and neurons. The results showed that there were more female patients than male patients with a ratio of 1:2. The results of this study were in accordance with the prevalence data of CKD patients, i.e. 67% female patients and 33% male patients. A study by Hill et al., (2015) found that 38 out of 51 studies showed that the prevalence of CKD incidence in females was higher than that in males. The prevalence of CKD stage 3-5 was found in females as much as 12.1% (10.6-13.8%) while in males 8.1% (6.3-10.2%). This finding differed from the results of the study by Singh et al. who compared hearing function in stage 3 to 5 CKD patients. The study found that patients undergoing conservative therapy and hemodialysis 40% were female and 60% were male. A study by Acharya and Nayak found a ratio of male patients to female patients of 4:1. A study by Singh et al. found no correlation between the severity of hearing loss in CKD patients and sex. Sex is not a major risk factor for chronic kidney disease because it is also influenced by race, genetic factors, and environment. Chronic kidney disease is a multifactorial disease. Some of the factors that make women more likely to develop chronic kidney disease are preeclampsia, urinary tract infections, lupus, and cervical cancer.

This study showed an increase in the incidence of CKD with

### Table 1. Sex and age distribution of the patients with CKD stage 3-5.

| Age (years) | Male | Female | N | %  |
|------------|------|--------|---|----|
| ≤30 years  | 0    | 1      | 1 | 3.3|
| 31-40      | 1    | 2      | 3 | 10.0|
| 41-50      | 5    | 4      | 9 | 30.0|
| 51-60      | 4    | 13     | 17| 56.7|
| Total      | 10   | 20     | 30| 100|

Mean±SD (min-max) 49.23±8.09 (30-60)
increasing age. Most CKD patients were in 51-60 years age group, consisting of 56.7% of the patients. The highest prevalence of CKD in Indonesia is in the age group 45 to 64 years. At the age of less than 25 years the prevalence was 2.57%. Increasing age will affect the anatomy, physiology and cytology of the kidneys. After 30 years of age the kidneys will experience atrophy and the thickness of the renal cortex will decrease by about 20% every decade.

The results of this study were similar to those of Vilayur’s study, as cited by Yamamoto et al., who found that the prevalence of CKD in those aged 50-59 years was 4.2% and increased to 52.2% at the age of 80-99 years. In this study, the age was limited to 60 years to avoid prebiacusis bias, so we could not observe the prevalence at those over 60 years of age. Gabr et al.’s study found no statistically significant difference between groups of normal people, CKD patients with or without hemodialysis based on sex and age with p>0.01.

Table 2. DPOAE examination results based on correlations of all frequencies.

| DPOAE results | CKD Stages 3-5 | n (%) | BUN level Mean±SD (Min-Max) | r (p) |
|---------------|---------------|-------|-----------------------------|-------|
| Refer         | 25            | 83.3% | Refer                       |       |
| Pass          | 5             | 16.7% | Refer                       |       |
| Total         | 30            | 100   |                             |       |

Table 3. Correlation between cochlear outer hair cell function and the BUN value.

| Frequency  | SNR Mean±SD (min-max) | Cochlear OHC function status | n (%) | BUN level Mean±SD (Min-Max) | r (p) |
|------------|-----------------------|-------------------------------|-------|----------------------------|-------|
| 1500 Hz    | 9.40±6.58 (0-21)      | Pass                          | 21 (70.0%) | 68.86±30.86 (20-117) | -0.317 |
|            | Refer                 |                               | 9 (30.0%) | 86.67±35.56 (38-144) | 0.088  |
| 2000 Hz    | 12.77±7.56 (1-30)     | Pass                          | 24 (80.0%) | 69.46±33.15 (20-114) | -0.218 |
|            | Refer                 |                               | 6 (20.0%) | 96.17±24.20 (77-137) | 0.246  |
| 3000 Hz    | 9.77±7.22 (0-23)      | Pass                          | 17 (56.7%) | 73.12±31.14 (20-117) | -0.058 |
|            | Refer                 |                               | 13 (43.3%) | 77.00±35.83 (26-144) | 0.761  |
| 4000 Hz    | 11.13±8.48 (0-25)     | Pass                          | 17 (56.7%) | 76.00±33.15 (20-117) | 0.051  |
|            | Refer                 |                               | 13 (43.3%) | 73.23±34.15 (26-144) | 0.767  |
| 5000 Hz    | 8.87±7.98 (0-26)      | Pass                          | 17 (56.7%) | 77.24±35.23 (20-114) | 0.095  |
|            | Refer                 |                               | 13 (43.3%) | 71.62±31.00 (26-137) | 0.617  |
| 6000 Hz    | 6.10±7.81 (0-24)      | Pass                          | 11 (36.7%) | 67.64±38.50 (20-117) | -0.054 |
|            | Refer                 |                               | 19 (63.3%) | 78.95±29.74 (38-144) | 0.775  |
| 7000 Hz    | 5.53±8.70 (0-32)      | Pass                          | 10 (33.3%) | 69.70±38.04 (20-117) | -0.085 |
|            | Refer                 |                               | 20 (66.7%) | 77.35±30.96 (29-144) | 0.656  |
| 8000 Hz    | 3.27±7.79 (0-33)      | Pass                          | 5 (16.7%) | 77.00±38.39 (22-117) | -0.030 |
|            | Refer                 |                               | 25 (83.3%) | 74.36±32.73 (20-144) | 0.874  |
| 9000 Hz    | 3.07±6.94 (0-26)      | Pass                          | 5 (16.7%) | 58.80±36.19 (22-110) | 0.220  |
|            | Refer                 |                               | 25 (83.3%) | 78.00±32.18 (22-144) | 0.242  |
| 10000 Hz   | 3.13±7.41 (0-34)      | Pass                          | 6 (20.0%) | 83.17±37.51 (22-117) | -0.129 |
|            | Refer                 |                               | 24 (80.0%) | 72.71±32.35 (22-144) | 0.497  |
| 11000 Hz   | 1.60±5.40 (0-27)      | Pass                          | 2 (6.7%)  | 87.50±31.82 (65-110) | -0.105 |
|            | Refer                 |                               | 28 (93.3%) | 73.89±33.48 (20-144) | 0.583  |
| 12000 Hz   | 1.03±4.26 (0-23)      | Pass                          | 1 (3.3%)  | 110.00±0.00 (110-110) | -0.201 |
|            | Refer                 |                               | 29 (96.7%) | 73.59±32.92 (20-144) | 0.286  |

Chronic kidney disease has a high prevalence of hearing loss up to 80%, with the location of the main lesion, based on ABR examination, in the cochlea and some in the retrochoclea. Based on OAE examination in CKD patients, cochlear dysfunction showed a varying prevalence from 40% to 95.65%. A study by Govender et al. in 50 CKD stage 1-5 patients showed impaired cochlear function at high frequency at stage 3-5 CKD. Subclinical hearing loss was present in 50% of the patients, in whom DPOAE results were abnormal, but ANM was normal. Distortion product otoacoustic emissions can detect initial cochlear damage, making it superior to audiometry as a screening tool. The high prevalence of hearing loss is an aspect that needs to be considered in the management of CKD patients. Hearing loss in CKD is associated with impaired cochlear function primarily due to damage to cochlear hair cells. Several studies have found abnormal OAE results but with normal ANM. These findings support OAE sensitivity to detect abnormalities in the cochlea before the hearing threshold develops in CKD patients.

In this study we obtained the prevalence of cochlear OHC function disorders based on DPOAE results in non-dialysis stage 3-5 CKD patients. We obtained refer results in 25 patients (83.3%). A research by Pandey, as cited by Hong et al. obtained the results of DPOAE showing that refer status was found in 63.04% of 23 patients (46 ears) of CKD, and the transitory evoked otoacoustic emission (TEOAE) examination revealed refer status in 95.65% of the patients. A follow-up examination using ABR to evaluate the retrochoclea found no retrochoclear involvement. A total of 65.21% of patients had abnormalities in the cochlea.

The causes of hearing loss in CKD are still being debated. One of the factors that are thought to play a role in the pathophysiology of hearing loss in patients with CKD is associated with uremia.
In chronic kidney disease there is a decrease in kidney excretory function and causes a buildup of protein metabolism waste, resulting in high concentrations of non-protein nitrogen, especially urea, creatinine and uric acid. Toxic metabolic waste causes tissue damage and malfunctioning of several organs, including the cochlea. The amount of urea in the blood is determined by the protein diet and the ability of the kidneys to excrete urea. In damaged kidneys, urea will accumulate in the blood. Serum urea levels reflect the balance between production and excretion. The BUN value may increase if protein is consumed in large quantities. However, excess urea will be excreted into the urine so that there is no significant increase in plasma urea.

Adler’s study, cited by Shomashekara et al., reported that in uremic conditions there was a reduction in Na+/K+ adenosin triphosphatase in the ear. Inhibition of action on this enzyme may be the cause of hearing loss, because Na+/K+-activated ATPase in the cochlea plays an important role in maintaining the balance of cationic gradient. Impaired balance of cationic gradient of endolymphatic fluid may have negative impact on hearing. A study by Govender, as cited by Saeed et al., regarding cochlear function in CKD stage 1-5 patients found a significant difference between BUN level and decreased cochlear function in patients with CKD stage 3-5. A study by Meena, as cited by Boateng et al. on 50 CKD patients compared to normal people, found an increase in BUN levels in CKD patients with sensorineural hearing loss, but there was no increase in the number of CKD patients related to the increase in BUN levels. In a study by Somashekara et al. on 60 CKD patients, CKD group with hearing loss showed an increase in BUN and serum creatinine levels, but there was no significant correlation.

This study did not find a significant correlation between impaired cochlear OHC function and increased BUN level. This study was in accordance with Kusakari’s study, as cited by Fufure et al., which reported that inner ear disorders were not correlated with BUN and serum creatinine level or with urea nitrogen, creatinine, potassium, sodium, calcium, and serum glucose levels. A research by Reddy et al. reported that hearing loss was not correlated with age, sex, BUN, serum creatinine, blood glucose levels, diastolic blood pressure, and hemoglobin (p>0.05), but it had correlation with disease duration (p=0.001). In this study we found impaired cochlear OHC function in 83.3% of non-dialysis CKD stage 3-5 patients, but found no significant correlation with increased BUN. DPOAE examination at each frequency in non-dialysis CKD stage 3-5 patients showed refer category mostly at a frequency of 12,000 Hz as much as 96.7% and a frequency of 11,000 Hz as much as 93.3%. The pass category was mostly at a frequency of 2000 Hz, as much as 80.0%. The results of this study indicated that OHC function disorder was more frequent at high frequencies, starting from the frequency of 6000 Hz.

A study of Seo et al. used a large sample size of 5,226 patients, and they found differences in BUN levels (p<0.001) between CKD patients with hearing loss and without hearing loss. Multiple linear regression analysis of hearing threshold with several parameters of renal function showed that there was no significant correlation between BUN and hearing loss (p=0.08) in CKD patients. Patients who had eGFR of <60 had a worse hearing threshold than patients with eGFR of >60. With multiple logistic analysis the significant result was obtained (OR, 1.25; 95% CI, 1.12–1.64; p<0.001). High urea condition affects the function of various organ systems and patients with CKD may experience various complications due to chronic renal dysfunction or the body’s adaptation mechanisms to disturbed body homeostasis.

Increased plasma urea indicates renal failure in filtration function. The condition of kidney failure is characterized by very high plasma urea levels above 50 mg/dl, which is known as uremia. Urea increases serum osmolarity, resulting in differences in osmotic gradient between inner ear fluids. The presence of urea transporters- (UT-A) and UT-B in pillar cells and Deiters cells plays an important role in the urea transport system between endolymph and perilymph. The osmotic effect of urea causes a decrease in the amount of endolymph fluid, which can affect hearing. In addition to causing osmolarity disorders, cochlear fluid, urea toxins can also cause hearing loss through uremic neuropathy of the auditory nerve.

Conclusions

No correlation was found between increased blood urea nitrogen levels and cochlear outer hair cell function disorders in non-dialysis patients with CKD stage 3-5.

Correspondence: Nyilo Purnami, Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine, Universitas Airlangga - Soetomo Academic Medical Center, Jalan Mayjen Prof. Dr. Moestopo no. 6-8, Airlangga, Gubeng, 60286, Surabaya, East Java, Indonesia. Tel. +62.8155100081. E-mail: nyilo@fk.unair.ac.id

Key words: Blood urea nitrogen; outer auditory hair cells; renal dialysis; hearing loss; chronic renal insufficiency; uremia.

Contributions: NP, AA, NM, conceptualization; NP, AR, AA, NM, data curation; NP, AR, NM, formal analysis; AR, AA, methodology; AR, project administration; NP, AR, writing – original draft; NP, AA, NM, writing – review & editing. All the authors have read and approved the final version of the manuscript and agreed to be accountable for all aspects of the work.

Conflict of interest: The authors declare no conflict of interest.

Availability of data and materials: All data generated or analyzed during this study are included in this published article.

Ethics approval: This study had met the ethical clearance procedure before the conducting of the study at Soetomo Hospital, Surabaya, with ethical clearance number 1661/KEPK/XI/2019.

Informed consent: The manuscript does not contain any individual person’s data in any form.

Received for publication: 15 July 2021. Accepted for publication: 21 November 2021.

©Copyright: the Author(s), 2022
Licensee PAGEPress, Italy
Journal of Public Health Research 2022;11:2533
doi:10.4081/jphr.2022.2533
This work is licensed under a Creative Commons Attribution NonCommercial 4.0 License (CC BY-NC 4.0).

References

1. World Health Organization. The World Health Organization’s message for world hearing day 2018. 2018 Accessed: 2019 March 31. Available from: http://www.who.int/deafness/world-hearing-day/whd2018/en/
2. Krajewska J, Krajewski W, Zatonski T. Otorhinolaryngological dysfunctions induced by chronic kidney disease in pre- and
post–transplant stages. Eur Arch Otorhinolaryngol 2020;277:1575-91.
3. Boateng JO, Boafo N, Osafo C, Anim-Sampong S. Hearing impairment among chronic kidney disease patients on haemodialysis at a tertiary hospital in Ghana. Ghana Med J 2019;53:197-203.
4. Cuna V, Battaglino G, Capelli I, et al. Hypoacusia and chronic renal dysfunction: new etiopathogenetic prospective. Ther Apher Dial 2015;19:111-18.
5. Liu W, Meng Q, Wang Y, et al. The association between reduced kidney function and hearing loss: a cross-sectional study. BMC Nephrol 2020;21:145.
6. Balasubramanian C, Santhanakrishnakumar B, Anandan H. A study of hearing loss in chronic renal failure. Int J Sci Study 2018;5:15-8.
7. Seo YJ, Ko SB, Ha TH, et al. Association of hearing impairment with chronic kidney disease: a cross-sectional study of the Korean general population. BMC Nephrol 2015;16:1-7.
8. Arnold R, Issar T, Krishnan AV, Russel BA. Neurological complications in chronic kidney disease. JRSM Cardiovasc Dis 2016;5:1-13.
9. Guyton AC, Hall JE. [Diuretics and renin renin-angiotensin system]. In: Ermita I, Ilyas I, Widjajakusumah MD, Tanzil A, editors. [Buku ajar fisiologi kedokteran - Diuretics and kidney diseases]. [Book in Indonesian]. 12th ed. Singapore: Elsevier; 2016. p. 392-406.
10. Rao SU, Subbaiah CHV, Haritha N. Evaluation of cochlear functions in renal failure by pure tone audiometry. IJCMR 2017:4:1-7.
11. Somashekara KG, Gowda BVC, Smitha SG, Mathew AS. Etiological evaluation of hearing loss in chronic renal failure. Indian J Basic Appl Med Res 2015;4:194-9.
12. Guyton AC, Hall JE. [Ekstreseluler fluid concentration]. In: Ermita I, Ilyas I, Widjajakusumah MD, Tanzil A, editors. [Buku ajar fisiologi kedokteran - Diuretics and kidney diseases]. [Book in Indonesian]. 12th ed. Singapore: Elsevier; 2016. p. 339-56.
13. Reddy EK, Surya Prakash DR, Rama Krishna MG. Proportion of hearing loss in chronic renal failure: Our experience. Indian J Otol 2016;22:4-9.
14. Lara-Sanchez H, Calvo DH, Sanudo EG, et al. Characterization of hearing loss in adult patients with nondialysis chronic kidney disease. Otol Neurotol 2020;41:776-82.
15. Saeed HK, Al-Abbasi AM, Al-Maliki SK, Al-Asadi JN. Sensorineural hearing loss in patients with chronic renal failure on hemodialysis in Basrah, Iraq. Ci Ji Yi Xue Za Zhi 2018;30:216-20.
16. Gabr TA, Kotait MA, Okda HI. Audiovestibular functions in chronic kidney disease in relation to haemodialysis. J Laryngol Otol 2019;133:592-9.
17. Jiang M, Karasawa T, Steyger PS. Aminoglycoside-induced cochleotoxicity: a review. Front Cell Neurosci 2017;11:1-14.
18. Singh KK, Trivedi A, Jain N, Iriteza M. To study auditory functions in chronic kidney disease. Indian J Otol 2018;24:261-5.
19. Mudhol RS, Jahnavi. Hearing evaluation in patients with chronic renal failure: A 1 year cross-sectional study in a tertiary care centre. Indian J Otolaryngol Head Neck Surg 2019;71:S1633-8.
20. Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease – A systematic review and meta-analysis. PLoS One 2016;11:1-18.
21. Acharya S, Pati N, Nayak AA. Pattern of hearing loss in patients of chronic kidney disease- a prospective comparative study. J Evol Med Dent Sci 2017;6:3656-9.
22. Duan J, Wang C, Liu D, et al. Prevalence and risk factors of chronic kidney disease and diabetic kidney disease in Chinese rural residents: a cross-sectional survey. Sci Rep 2019;9:10408.
23. Indonesian Renal Registry. 11th Report of Indonesian Renal Registry. Jakarta: Indonesian Renal Registry; 2018. p. 1–46.
24. Yamamoto K, Kurioka T, Furuki S, et al. Clinical features and hearing prognosis of idiopathic sudden sensorineural hearing loss in patients undergoing hemodialysis: A retrospective study. Laryngoscope Investig Otolaryngol 2021;6:1104-9.
25. Hong JW, Jeon JH, Ku CR, et al. The prevalence and factors associated with hearing impairment in the Korean adults: the 2010-2012 Korea National Health and Nutrition Examination Survey (observational study). Medicine (Baltimore) 2015;94:e611.
26. Fufore MB, Kirfi AM, Salisu AD, et al. Hearing loss in chronic kidney disease: An assessment of multiple aetiological parameters. Otolaryngol 2020;10:1000393.
27. Wu K-L, Shih C-P, Chan J-S, et al. Investigation of the relationship between sensorineural hearing loss and associated comorbidities in patients with chronic kidney disease: A nationwide, population based cohort study. PLoS One 2020;15:e0238913.
28. Saha P, Mondal P. Study of prevalence and pattern of sensorineural hearing impairment in stage 5 chronic kidney disease patients on haemodialysis- at a tertiary health care setup in India. IJMSDR 2020;4:1-7.
29. Somashekara KG, Gowda CBV, Smitha SG, Mathew AS. Etiological evaluation of hearing loss in chronic renal failure. Indian J Basic Appl Med Res 2015;4:194-9.
30. Prasad V, Sreedharan S, Bhat J, Hegde MC, Waheeda C, Agarwal S. Hearing loss in chronic renal failure - An assessment of multiple aetiiological factors. Otolaryngol Online J 2015; 5.